|
Real-time
Euronext Paris
03:35:12 29/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 0.7350 EUR | +8.09% |
|
+8.41% | -23.44% |
| 05/10 | Transgene to present preclinical data on PoxSTG-EEV |  |
| 25/09 | Transgene provides update on its operations | |
Company Valuation: Transgene
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 247.8 | 164.8 | 137.8 | 89.75 | 262.9 | 186.2 | - | - |
| Change | - | -33.52% | -16.38% | -34.86% | 192.89% | -29.15% | - | - |
| Enterprise Value (EV) 1 | 214.9 | 151.4 | 139.4 | 83.48 | 153.1 | 117 | 178.5 | 204.8 |
| Change | - | -29.53% | -7.95% | -40.12% | 83.37% | -23.54% | 52.55% | 14.73% |
| P/E | -12.1x | -5.02x | -6.23x | -2.34x | -3.69x | -4.86x | -3.09x | -7.56x |
| PBR | 3.69x | 4.38x | 8.82x | 5.92x | 1.14x | 2.27x | 8.5x | -68x |
| PEG | - | -0.1x | 0.2x | -0.1x | 0.4x | 0.1x | -0.1x | 0.1x |
| Capitalization / Revenue | 14.2x | 15.9x | 17.4x | 14.1x | 36.5x | 25.9x | 25.9x | 3.26x |
| EV / Revenue | 12.3x | 14.6x | 17.6x | 13.1x | 21.2x | 16.3x | 24.8x | 3.58x |
| EV / EBITDA | -10.2x | -5.37x | -4.9x | -2.43x | -4.54x | -2.68x | -2.55x | -8.68x |
| EV / EBIT | -9.14x | -5.06x | -4.64x | -2.34x | -4.37x | -2.64x | -2.52x | -6.99x |
| EV / FCF | -6.59x | -6.94x | -1,408x | -3.12x | -1.07x | -2.95x | -2.96x | -8.16x |
| FCF Yield | -15.2% | -14.4% | -0.07% | -32% | -93.4% | -33.9% | -33.8% | -12.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.21 | -0.33 | -0.22 | -0.29 | -0.26 | -0.14 | -0.22 | -0.09 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 17.41 | 10.34 | 7.9 | 6.353 | 7.21 | 7.2 | 7.2 | 57.2 |
| EBITDA 1 | -21 | -28.22 | -28.48 | -34.38 | -33.73 | -43.6 | -70.1 | -23.6 |
| EBIT 1 | -23.52 | -29.9 | -30.05 | -35.66 | -35.06 | -44.3 | -70.8 | -29.3 |
| Net income 1 | -19.54 | -32.8 | -22.33 | -33.97 | -37.52 | -38.2 | -61.6 | -25.3 |
| Net Debt 1 | -32.93 | -13.31 | 1.629 | -6.274 | -109.8 | -69.2 | -7.7 | 18.6 |
| Reference price 2 | 2.5400 | 1.6580 | 1.3700 | 0.6800 | 0.9600 | 0.6800 | 0.6800 | 0.6800 |
| Nbr of stocks (in thousands) | 97,576 | 99,370 | 100,566 | 131,990 | 273,827 | 273,882 | - | - |
| Announcement Date | 16/3/22 | 16/3/23 | 27/3/24 | 27/3/25 | 24/3/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.86x | 16.26x | -2.68x | - | 208M | |
| 17.08x | 6.33x | 12.4x | 1.75% | 63.48B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 54.55B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.59B | |
| 35.05x | 3.37x | 14.55x | -.--% | 44.75B | |
| 48.28x | 5.55x | 30.42x | -.--% | 41.62B | |
| -19.33x | 186.93x | -20.57x | -.--% | 39.91B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.47B | |
| 36.51x | 6.64x | 22.27x | -.--% | 26.7B | |
| 26.96x | 5.67x | 14.71x | -.--% | 23.36B | |
| Average | 23.70x | 25.32x | 13.74x | 0.34% | 38.06B | |
| Weighted average by Cap. | 26.53x | 25.23x | 15.67x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TNG Stock
- Valuation Transgene
Select your edition
All financial news and data tailored to specific country editions
